Chemistry:List of aminorex analogues

From HandWiki
Short description: none


This is a list of aminorex analogues, also known as substituted 2-amino-5-aryloxazolines. Aminorex itself is a stimulant drug with a 5-phenyl-2-amino-oxazoline structure. It was developed in the 1960s as an anorectic,[1][2][3] but withdrawn from sale after it was discovered that extended use produced pulmonary hypertension, often followed by heart failure, which resulted in a number of deaths.[4] A designer drug analogue 4-methylaminorex appeared on the illicit market in the late 1980s but did not attract significant popularity due to its steep dose-response curve and tendency to produce seizures.[5][6][7][8] Pemoline, the 4-keto derivative of aminorex, had been discovered several years earlier,[9] and derivatives of this type appeared to be effective stimulants with comparatively low toxicity.[10][11] Pemoline was sold for around 25 years as a therapy for ADHD and relief of fatigue, before being withdrawn from the market in 2005 because of rare but serious cases of liver failure.[12][13][14][15] More recently in around 2014 another derivative 4,4'-dimethylaminorex started to be sold illicitly, but again swiftly lost popularity due to a spate of fatal overdose cases.[16][17][18] A number of related compounds are known, and new derivatives have continued to appear on the designer drug market.[19][20][21][22][23][24]

List of substituted aminorex derivatives

Template:Sticky

See also

References

  1. ↑ Meschino JA, Poos GI. 2-amino-5,6-dihydro-4H-1,3-oxazines and a process for their preparation. US Patent 3115494, 1961
  2. ↑ Poos GI. 2-amino-5-aryloxazoline products. US Patent 3161650, 1962
  3. ↑ "2-Amino-5-aryl-2-oxazolines. Potent New Anorectic Agents". Journal of Medicinal Chemistry 6 (3): 266–272. May 1963. doi:10.1021/jm00339a011. PMID 14185981. 
  4. ↑ "Aminorex and pulmonary hypertension. A review". Cor et Vasa 27 (2–3): 160–171. 1985. PMID 3928246. 
  5. ↑ "A fatality involving U4Euh, a cyclic derivative of phenylpropanolamine". Journal of Forensic Sciences 33 (2): 549–553. March 1988. doi:10.1520/JFS11971J. PMID 3373171. 
  6. ↑ "Neurochemical effects of an acute treatment with 4-methylaminorex: a new stimulant of abuse". European Journal of Pharmacology 180 (1): 103–111. May 1990. doi:10.1016/0014-2999(90)90597-y. PMID 1973111. 
  7. ↑ "Recreational use of aminorex and pulmonary hypertension". Chest 118 (5): 1496–1497. November 2000. doi:10.1378/chest.118.5.1496. PMID 11083709. 
  8. ↑ "Rewarding properties of the stereoisomers of 4-methylaminorex: involvement of the dopamine system". Pharmacology, Biochemistry, and Behavior 81 (4): 715–724. August 2005. doi:10.1016/j.pbb.2005.04.020. PMID 15982727. 
  9. ↑ Schmidt L, Scheffler H. Central nervous system stimulant. US Patent 2892753, 1957
  10. ↑ "Hardy RA, Howell CF, Quinones NQ. Method of producing central nervous system stimulation and anorexia. US Patent 3313688, 1964". https://patents.google.com/patent/US3313688. 
  11. ↑ "Guidicelli DP, Najer H. 5-phenyl-2-cyclopropylamino-4-oxazolinone, and process for making the same. US Patent 3609159, 1967". https://patents.google.com/patent/US3609159. 
  12. ↑ "Pemoline hepatotoxicity in children". The Journal of Pediatrics 132 (5): 894–897. May 1998. doi:10.1016/s0022-3476(98)70329-4. PMID 9602211. 
  13. ↑ "Pemoline hepatotoxicity and postmarketing surveillance". Journal of the American Academy of Child and Adolescent Psychiatry 40 (6): 622–629. June 2001. doi:10.1097/00004583-200106000-00006. PMID 11392339. 
  14. ↑ "A surveillance method for the early identification of idiosyncratic adverse drug reactions". Drug Safety 31 (2): 169–180. 2008. doi:10.2165/00002018-200831020-00006. PMID 18217792. 
  15. ↑ "Risk Evaluation and Mitigation Strategies (REMS), Pemoline, and What Is a Signal?". Clinical Therapeutics 39 (4): 665–669. April 2017. doi:10.1016/j.clinthera.2017.03.008. PMID 28366595. 
  16. ↑ "Characterization of a novel and potentially lethal designer drug (±)-cis-para-methyl-4-methylaminorex (4,4'-DMAR, or 'Serotoni')". Drug Testing and Analysis 6 (7–8): 684–695. 2014. doi:10.1002/dta.1668. PMID 24841869. 
  17. ↑ "4,4'-DMAR: chemistry, pharmacology and toxicology of a new synthetic stimulant of abuse". Basic & Clinical Pharmacology & Toxicology 117 (1): 26–30. July 2015. doi:10.1111/bcpt.12399. PMID 25819702. 
  18. ↑ "The psychostimulant (±)-cis-4,4'-dimethylaminorex (4,4'-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters". Neuropharmacology 138: 282–291. August 2018. doi:10.1016/j.neuropharm.2018.06.018. PMID 29908239. 
  19. ↑ "Stimulus properties of some analogues of 4-methylaminorex". Pharmacology, Biochemistry, and Behavior 51 (2–3): 375–378. 1995. doi:10.1016/0091-3057(94)00407-a. PMID 7667356. 
  20. ↑ "The effects of aminorex and related compounds on brain monoamines and metabolites in CBA mice". The Journal of Pharmacy and Pharmacology 49 (1): 89–96. January 1997. doi:10.1111/j.2042-7158.1997.tb06758.x. PMID 9120777. 
  21. ↑ "Synthesis, characterization, and monoamine transporter activity of the new psychoactive substance 3',4'-methylenedioxy-4-methylaminorex (MDMAR)". Drug Testing and Analysis 7 (7): 555–564. July 2015. doi:10.1002/dta.1732. PMID 25331619. 
  22. ↑ "DARK Classics in Chemical Neuroscience: Aminorex Analogues". ACS Chemical Neuroscience 9 (10): 2484–2502. October 2018. doi:10.1021/acschemneuro.8b00415. PMID 30269490. 
  23. ↑ "Characterization of a recently detected halogenated aminorex derivative: para-fluoro-4-methylaminorex (4'F-4-MAR)". Scientific Reports 9 (1): 8314. June 2019. doi:10.1038/s41598-019-44830-y. PMID 31165778. Bibcode: 2019NatSR...9.8314F. 
  24. ↑ "Pharmacological characterization of the aminorex analogs 4-MAR, 4,4'-DMAR, and 3,4-DMAR". Neurotoxicology 72: 95–100. May 2019. doi:10.1016/j.neuro.2019.02.011. PMID 30776375. Bibcode: 2019NeuTx..72...95R. 
  25. ↑ "Pharmacology of ephedroxanes". Journal of Ethnopharmacology 13 (2): 175–191. May 1985. doi:10.1016/0378-8741(85)90005-4. PMID 4021515.